Dementia with Lewy bodies is a progressive neurodegenerative dementia characterized by cognitive decline, fluctuations in attention and alertness, visual hallucinations, REM sleep behavior disorder, and parkinsonism.
CervoMed presents new MRI data showing neflamapimod may reduce basal forebrain atrophy in dementia with Lewy bodies and finalizes Phase 3 trial design. The drug has also been selected for a UK-funded ALS platform trial, with first dosing expected by end of 2026.
Researchers have identified DOPA decarboxylase as a quantitative biomarker in cerebrospinal fluid that improves diagnosis of Parkinson's disease and Lewy body dementia. The protein levels are up to 2.5 times higher in affected patients and can differentiate these conditions from Alzheimer's disease. The discovery provides clinicians with an objective diagnostic tool for conditions that are frequently misdiagnosed due to overlapping symptoms.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06961760 |
Expanded Access Program for CT1812 (Zervimesine) |
NO_LONGER_AVAILABLE | |
| NCT05869669 |
RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies |
COMPLETED | PHASE2 |
| NCT05826457 |
North American Prodromal Synucleinopathy Consortium Stage 2 |
ENROLLING_BY_INVITATION | |
| NCT04588285 |
Ambroxol in New and Early DLB, A Phase IIa Multicentre Randomized Controlled Double Blind Clinical Trial |
RECRUITING | PHASE2 |
| NCT03672266 |
Studies of Brain and Body Interaction |
COMPLETED | |
| NCT00917709 |
Imaging of Vesicular Acetylcholine and Dopamine Transporters in Dementia With Lewy Bodies |
COMPLETED | NA |
